Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer Via Analysis of Immunoinflammation-related Protein Complexes in Blood
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- immune inflammation-related protein complexes
Overview
Brief Summary
The relationship between immune inflammation-related protein complexes in blood and recurrence or metastasis of breast cancer will be studied.
Detailed Description
200 patients with breast cancer will be followed up. Peripheral venous blood was collected every 3 to 6 months. Change regularity of breast cancer-specific immune inflammation-related protein complexes in blood at different follow-up time points will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- — to 60 Years (Child, Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Postoperative pathology confirmed invasive breast cancer after surgery for breast tumors
- •Breast cancer-related chemotherapy and radiotherapy completed
- •axillary lymph node metastasis ≥ 4
- •age ≤ 60 years old
Exclusion Criteria
- •Aged above 60
- •Breast Carcinoma in situ
- •Women in pregnancy or breastfeeding
- •Suffering from other malignant tumors
- •Non-compliant patient
Outcomes
Primary Outcomes
immune inflammation-related protein complexes
Time Frame: 2 years
The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
blood markers
Time Frame: 2 years
The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
Secondary Outcomes
No secondary outcomes reported
Investigators
Yali XU
Principal Investigator
Peking Union Medical College Hospital